Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cergutuzumab Amunaleukin + Atezolizumab in Advanced Solid Tumors
NCT02350673Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2015
- Primary completion
- Dec 2019
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of cergutuzumab amunaleukin in solid tumor (2 arms), sponsored by Roche. Primary endpoints: Number of Participants with Dose-Limiting Toxicities, Maximum Tolerated Dose of Cergutuzumab Amunaleukin and 3 more. Started Jun 2015; status: completed.
02
Drugs
cergutuzumab amunaleukin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02350673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02350673.